Voltar à classificação

Thermo Fisher Scientific Inc (TMO)

Superavaliada
HealthcareDiagnostics & ResearchUnited States

Fundamental

61

Preço

$675.05

Capitalização de Mercado

$250.91B

Parte 1 · Quanto vale a empresa

Visão Geral

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balanço & Liquidez

Receita

$46.34B

Últimos 12 meses (até 27/06/2026)

Resultado Líquido

$6.97B

Últimos 12 meses (até 27/06/2026)

Fluxo de Caixa Livre

$6.29B

Capital Próprio Total

$53.41B

Passivo Total

$56.93B

Rácio de Liquidez

1.55

Cobertura de Juros

5.46

Dívida/EBITDA

3.62

Resultados Por Ação

Receita & Resultado Líquido

Fluxo de Caixa Livre

Decomposição dos Resultados

Demonstração histórica

Margens ao longo do tempo

A dívida ao longo do tempo

Quanto pesa a dívida

Grelha do crescimento

Crescimento — Receitas

Estimativa de Valor Justo

Caso geralSobrevalorizada

Valor Justo

$437.42

Preço Atual

$675.05

Margem de Segurança

-54.3%

Intervalo de Valor Justo

$284.32 - $590.52

Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.

Métodos de Estimativa

Preço-alvo dos analistas:$653.11
Fluxo de caixa descontado (DCF):$291.26
Multiplicador de lucros (P/E):$455.96
Fórmula de crescimento de Graham:$207.75
Valor da capacidade de gerar lucro (EPV):$187.20
P/B justificado:$251.52
Desconto de dividendos (Gordon):$33.18
P/FFO, fundos de operações:Dados insuficientes para o calcular
Lucros de meio de ciclo:$349.15
Multiplicador sobre as receitas:$492.07
Consenso dos Analistas:Compra Forte (29B / 7H / 0S)
Última Surpresa de Resultados:+4.54%

Métricas de Avaliação

Rácio P/E

36.31

ROE

12.6%

Rácio P/B

4.74

P/FCF

34.11

Margem Bruta

-

ROIC

6.6%

Radar de Rentabilidade

Criação de Valor (Vantagem Competitiva)

ROIC

6.6%

WACC

8.3%

ROIC − WACC

-1.7 pp

O ROIC está abaixo do custo do capital — a empresa está a destruir valor a cada dólar investido.

Critérios de Análise Fundamental

Aprovado (19)

  • EPS shows upward trend
  • EPS CAGR 13.95%
  • Price CAGR 15.76%
  • ROIC 6.6%
  • Debt/Equity ratio
  • Operating Margin 17.6%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 13.3%
  • Revenue Growth 5Y 6.7%
  • Analyst Consensus 81% Buy
  • Earnings Surprise avg 3.2%
  • Earnings Quality (OCF/NI) 1.29
  • Share Dilution -1.4%
  • Piotroski F-Score 5/9

Reprovado (7)

  • P/FCF 34.11
  • P/B Ratio 4.74
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 16.99
  • Net Margin Trend 15.0% vs 15.2%

Indisponível (2)

  • Gross Margin NaN%
  • Dividend Payout NaN%

Piotroski F-Score

5/9

Sinais mistos: algumas áreas requerem atenção

score
criteria

Qualidade dos Resultados

1.29

Alta qualidade: resultados respaldados por caixa

Diluição de Ações

-1.4%

A recomprar ações. Favorável ao acionista

Participações institucionais

Governação

Equipa Executiva

NomeCargoIdade
Mr. Marc N. CasperChairman & CEO57
Mr. Gianluca PettitiPresident, COO & President of Products and Technologies46
Mr. James R. MeyerSenior VP & CFO45
Mr. Joseph R. HolmesVP & Chief Accounting Officer45
Mr. Ryan J. SnyderSenior VP & Chief Information Officer-
Dr. Karen E. Nelson Ph.D.Chief Scientific Officer-
Mr. Rafael TejadaVice President of Investor Relations-
Mr. Thomas Bailey Shropshire Jr.Senior VP and General Counsel-
Ms. Sandy B. PoundVP & Chief Communications Officer-
Mr. Alan J. MalusSenior Vice President of Strategy & Corporate Development65

Risco de Auditoria

2

Risco do Conselho

7

Risco de Remuneração

10

Risco dos Direitos dos Acionistas

1

Parte 2 · O preço e o momento de entrar

Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.

Documentos

  • Relatório anual (10-K)

    Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.

    Arquivado em 2026-02-26

    Ver documento
  • Relatório trimestral (10-Q)

    Uma atualização sobre o desempenho financeiro dos últimos três meses.

    Arquivado em 2026-07-31

    Ver documento
  • Relatório de fato relevante (8-K)

    Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.

    Arquivado em 2026-07-23

    Ver documento

via SEC EDGAR

Histórico de Resultados

via SEC EDGAR

Latest News

Recent headlines for TMO, sourced from Markets Gazette.

  • 5/25/2026POSITIVE
    If You Invested $1000 In Thermo Fisher Scientific Stock 20 Years Ago, You Would Have This Much Today

    An investment of $1000 in Thermo Fisher Scientific (TMO) stock 20 years ago would have yielded a substantial return, illustrating the company's long-term growth trajectory. While the exact final value is not provided in this snippet, historical performance data suggests significant capital appreciation. This underscores Thermo Fisher's consistent operational success and market leadership in the life sciences and diagnostics sectors. Investors considering TMO should note its history of innovation and strategic acquisitions, which have contributed to its robust financial performance and shareholder value creation over the past two decades.

  • 3/12/2026POSITIVE
    Here's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today

    An investment of $100 in Thermo Fisher Scientific (TMO) 15 years ago would have grown to approximately $1,040 today, representing a substantial 940% return. This performance significantly outpaced the broader market during the same period. The company's consistent growth trajectory, driven by its diversified portfolio in life sciences, diagnostics, and laboratory products, has been a key factor in its stock's appreciation. Investors who held TMO stock have benefited from its strong operational execution and strategic acquisitions, underscoring its resilience and long-term value creation potential.

  • 3/2/2026NEUTRAL
    Here's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today

    A retrospective analysis highlights the remarkable performance of Thermo Fisher Scientific, revealing how a $100 investment made two decades ago would have generated substantial returns for today's investors. While this study doesn't provide direct future guidance, it underscores the company's ability to create long-term value, driven by its leadership in life sciences, diagnostics, and research. Consistent growth and innovation have allowed Thermo Fisher to solidify its market position, transforming a modest initial capital into a significantly larger sum. For investors, this serves as a reminder of the importance of patience and selecting companies with strong fundamentals and a lasting competitive advantage.

via Markets Gazette